522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer

Abstract

BackgroundThe standard treatment of relapsed small cell lung cancer (SCLC) has not been established yet, and weekly paclitaxel (PTX) is recommend as one of the treatment options for relapsed SCLC. In advanced non-small cell lung cancer, nanoparticle albumin-bound paclitaxel (nab-PTX) has shown equal activity to PTX with less neurological adverse event. However, the benefit of nab-PTX for relapsed SCLC has not been fully evaluated yet. The aim of this study is to evaluate efficacy and safety of both weekly nab-PTX and weekly PTX regimen for relapsed SCLC. MethodsWe retrospectively reviewed consecutive relapsed SCLC patients who were treated with weekly nab-PTX (80mg/m2, day1,8,15/q4 weeks) or weekly PTX (80mg/m2, day1,8,15,22/q4 weeks) at Tosei general hospital, from January 2008 to March 2019. We evaluated the objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse event profile in each regimen. ResultsA total of 52 patients with relapsed SCLC were reviewed, 18 and 34 patients received weekly nab-PTX (group A) and weekly PTX (group B), respectively. Patient characteristics (group A: group B) were as follows; male 17 (94%): 28(82%), median of age 74 :70, ECOG-PS 0-1 18(100%) :29(85%), extensive disease 14(78%) :17(50%), refractory relapse 16(89%) :20(59%). ORR in group A and B were 5.6% and 8.8%, and DCR in group A and B were 55.6% and 38%, respectively. The PFS and OS had no difference between group A and B (median PFS, 3.2months and 1.7months; median OS, 5.4 months and 4.5months). Toxicity profile of group A was tolerable as well as group B. About neurological adverse event, group A had less toxicity than group B in any grade (5(28%) and 12(35%) patients) but no severe adverse event was observed. ConclusionsWeekly nab-PTX and weekly PTX showed similar efficacy for relapsed SCLC. In terms of toxicity, weekly nab-PTX might be less toxic especially in neurological adverse event. Although this is a retrospective single center study, the nab-PTX might be a treatment option for relapsed SCLC. Legal entity responsible for the studyHajime Oi. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.